Marshall Wace shorts Elekta: 15.76 percent of Elekta stock is short

Published on 10/20/2026 at 12:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Marshall Wace raised its public short to 0.50 percent on October 16, 2026. Second-quarter results for Elekta stock are scheduled for November 25, 2026.

Short interest and operating reset

Marshall Wace disclosed a 0.50 percent public short position on October 16, 2026.
For fiscal year 2025/26, Elekta reported 1.00 percent net sales growth in constant exchange rates.
Elekta stock was valued at SEK 20.3 billion on October 20, 2026.

Pop-Art-Comic zeigt Arzt und stilisierte Bestrahlungsmaschine mit ZAP-Effekt — Farbenfrohe Pop-Art-Comic-Szene mit stilisierter Bestrahlungsmaschine symbolisiert humorvoll das Kerngeschäft von Elekta AB SE0000163628, Illustration mit AI erstellt.

Elekta (SE0000163628) is facing a newly disclosed 0.50 percent public short position after Marshall Wace increased its stake on October 16, 2026, according to MarketScreener. The report said total short interest reached 15.76 percent of Elekta's capital, giving the announcement a clear risk marker ahead of the next financial update.

Short interest reaches a public threshold

Marshall Wace's position crossed the 0.50 percent disclosure threshold used for public short positions in Sweden. The report also counted 13 public short sellers in Elekta, while total short interest stood at 15.76 percent of the company's capital, according to MarketScreener.

What does the operating reset show?

Elekta's fiscal year 2025/26 net sales increased 1.00 percent in constant exchange rates. The company said annualized cost savings exceeded SEK 500 million, while fourth-quarter adjusted EBIT margin reached 18.90 percent, compared with 16.30 percent a year earlier, according to Elekta. Net debt decreased to SEK 3.191 billion in the same fiscal year, making margin durability and balance-sheet progress the main counterpoints to the short-interest signal.

Three dated signals for Elekta

On September 29, 2026, Elekta presented phase two Gamma Knife data covering patients with up to 50 brain metastases, as reported by MarketScreener. On October 1, 2026, the first patient in Japan was treated with Elekta Evo at Hyogo Medical University Hospital, according to Elekta. On October 16, 2026, Marshall Wace lifted its public short position to 0.50 percent.

Next report date is November 25

Elekta's next scheduled reporting date is November 25, 2026, when the company plans to publish its second-quarter report, according to the investor calendar on Elekta. That report will test whether the cost reductions and improved adjusted EBIT margin seen in fiscal year 2025/26 are carrying into the new fiscal year.

Stock valuation before the report

Elekta was trading at SEK 55.40 on Nasdaq Stockholm on October 20, 2026 at 12:44 p.m. CEST. The company had a market capitalization of SEK 20.3 billion, with a 52-week range of SEK 41.86 to SEK 66.70 as of October 20, 2026.